Under the settlement, Medacta will receive a non-exclusive license to some Conformis patents related to patient-specific instruments with knee and shoulder implants, Conformis said Nov. 14. Medacta on Nov. 15 said the settlement also “contemplates the payment of a sum in a low single digit million-dollar amount.”
“Through this settlement, we have once again monetized our patient-specific instrument patents and steadfastly protected our patient-specific implant products and services,” Conformis President and CEO Mark Augusti said in a statement.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
